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Abstract
Background: There is limited data regarding the clinical utility of cystatin C in patients with
stable coronary artery disease (CAD). The aim of this study was to determine the predictive
value of cystatin C for the presence and severity of CAD and the association between this
protein and other biochemical risk factors for atherosclerosis in patients with suspected CAD.
Methods: Ninety-four patients with CAD, and 92 patients without CAD but with cardiovascu-
lar risk factors, were included in this study. Echocardiography and other pertinent laboratory
examinations were performed. Subjects were divided into four groups according to their cystatin C
quartile. Cystatin C groups were analyzed for the association with CAD characteristics.
Results: The number of patients with CAD increased as the quartile of cystatin C increased,
and there was a remarkable difference between quartiles (p < 0.001). Logistic regression analy-
sis revealed independent predictors of incident CAD as cystatin C, hs-CRP, eGFR, HDL choles-
terol and SBP (p = 0.005, p = 0.027, p = 0.017, p = 0.014 and p = 0.001, respectively). Moreover,
cystatin C concentration was significantly correlated with CAD severity score (b = 0.258,
p < 0.01). A cut-off value of 0.82 mg/L for cystatin C predicted incident CAD with a sensitivity
and specificity of 75.5% and 75.0% respectively. Cystatin C concentration also correlated well
with the atherosclerotic biochemical risk factors like homocysteine, creatinine and hs-CRP.
Conclusions: Cystatin C could be a useful laboratory tool in predicting the presence and
severity of CAD in daily practice. It also correlates significantly with biochemical risk factors
for CAD, namely homocysteine, low HDL and CRP. (Cardiol J 2010; 17, 4: 374–380)
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Introduction
Renal dysfunction has been identified as a risk
factor for the onset and prognosis of coronary athe-
rosclerosis, and is regarded as a coronary artery
disease (CAD) equivalent [1–3]. Although glome-
rular filtration rate (GFR) is a sensitive method for
assessing renal function, it has many drawbacks
such as difficulties in collecting urine. Therefore,
for practical reasons, estimated GFR (eGFR) is used
widely in clinical settings, and this primarily de-
pends on serum creatinine. However, serum crea-
tinine is not sensitive enough to detect mild renal
dysfunction [4]. Cystatin C is an endogenous gly-
cosylated protein produced in all nucleotide cells in
the human body and a novel marker for renal func-
tion [5]. It is more sensitive and specific for the es-
timation of GFR and less influenced by age, gen-
der, race, muscle mass and medication, as compared
to serum creatinine [4, 6, 7]. The use of cystatin C
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for the assessment of renal filtration function has
recently been approved [8].
Previous studies have shown a close relation-
ship between cystatin C and atherosclerotic disease
[9–11]. Furthermore, a high level of cystatin C has
been related to suspected or confirmed acute coro-
nary syndrome [12]. In 2007, the European Socie-
ty of Cardiology recommended the use of cystatin
C for predicting myocardial infarction and long-term
mortality in patients with non-ST elevation acute
coronary syndrome [13]. The results of studies in-
vestigating the value of cystatin C in anticipation
of atherosclerosis in suspected stable CAD patients
are controversial [10, 14–16]. Therefore, the clini-
cal utility of cystatin C in stable CAD patients me-
rits further investigation.
The aim of this study was to investigate the
predictive value of cystatin C level for the presence
or severity of CAD and the association between this
protein and other biochemical risk factors for athe-
rosclerosis in patients with suspected CAD.
Methods
Study group
Ninety-four CAD patients (70 male, 24 female,
mean age 57.8 ± 9.0 years) with significant coro-
nary stenosis (> 50%) and 92 subjects without CAD
but with cardiovascular risk factors (63 male,
29 female, mean age 55 ± 7 years) were included
in this cross-sectional study. Patients with severe
renal dysfunction (creatinine > 2 mg/dL), history
of recent acute coronary syndrome, valvular heart
disease, life-threatening arrhythmias, acute and
chronic liver disease, infectious and inflammatory
disease, and symptomatic heart failure were exclud-
ed. All patients were in a stable condition and tak-
ing optimal medical therapy for their cardiovascu-
lar risk factors. The local ethics committee ap-
proved the study and informed consent was
obtained from all subjects.
The detailed histories of patients, including
demographics data and cardiovascular risk factors,
were recorded. Serum cholesterols, homocysteine,
high sensitive C-reactive protein (hs-CRP), blood
urea nitrogen and creatinine levels were measured
by routine laboratory methods. GFR was estimat-
ed by the Cockcroft-Gault formula:
[(140  age) × weight (kg)]/[72 × serum creati-
nine (mg/dL)] (× 0.85 for women) [17].
Echocardiographic examination
All echocardiographic examinations were ob-
tained at rest. Standard echocardiographic imaging
was carried out by using a VIVID 7 machine (GE
Healthcare, Little Chalfont, United Kingdom) with
a 2.5 or 3.5 MHz phased array transducer. A single
experienced cardiologist (M.K.) performed echocar-
diography and the mean of three consecutive cycles
was used to drive the analysis. M-mode evaluation
was made according to the recommendations of the
American Society of Echocardiography [18]. The
left ventricular ejection fraction was calculated via
modified Simpson’s technique. The left ventricular
mass was calculated using the Devereux formula
[19] and indexed to body surface area. The presence
of left ventricular hypertrophy was accepted as left
ventricular mass index (LVMI) > 134 g/m2 for men
and > 110 g/m2 for women [20].
Coronary angiography
All patients underwent coronary angiography,
performed using standard Judkins techniques be-
fore the start of the study. Two expert investiga-
tors, blinded to the clinical data, analyzed the an-
giograms. The severity of coronary atherosclero-
sis was scored according to Gensini scoring [21] and
three CAD groups were drawn up according to their
CAD severity score: namely normal coronary arteries
(normal coronary arteries or score 0), mild CAD
(score = 1–20) and severe CAD (score > 20).
Assessment of cystatin C
Venous blood was withdrawn from resting pa-
tients, and put into ethylenediamine-tetraacetic acid
(EDTA)-containing tubes. Plasma was extracted
after blood samples had been centrifuged at 3,000 g
for 10 min at 0°C. Cystatin C was measured using
the particle-enhanced nephelometric immunoassay
(PENIA) method and N Lateks cystatin C kit (Dade
Behring, Marburg, Germany) on a BN ProSpec pro-
tein analyzer (Dade Behring, Marburg, Germany)
no more than 20 minutes after venipuncture.
Statistical analysis
All analyses were performed using SPSS ver-
sion 15.0 (SPSS Inc., Chicago, Illinois, USA). Cate-
gorical variables of cystatin C groups were com-
pared by the chi-square test. Continuous variables
were expressed as mean ± SD and compared by
one-way analysis of variance. When indicated, a post
hoc test (Scheffe or Tamhane) was performed. Cor-
relations between continuous variables were as-
sessed using Pearson’s or Spearman’s rank corre-
lation analysis. Multivariate logistic regression anal-
yses were performed to determine significant
predictors of CAD. Significant variables in univari-
ate analysis at a p < 0.1 level was entered in logis-
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tic regression analysis. Moreover, a linear regres-
sion analysis was applied for CAD severity score,
homosysteine and hs-CRP levels. A receiver-ope-
rating characteristic (ROC) curve analysis was per-
formed to identify the optimal cut-off points of cys-
tatin C and CRP levels (to determine maximal sen-
sitivity and specificity) for predicting CAD. The area
under the curve value was calculated to determine
accuracy of the test. A p value of < 0.05 was con-
sidered as statistically significant.
Results
Cystatin C concentration was significantly
elevated in the CAD group compared to normal
coronary arteries patients (1.04 ± 0.38 and 0.70 ±
± 0.25 mg/L respectively, p < 0.001). Clinical, lab-
oratory, angiographic and echocardiographic vari-
ables of cystatin C quartile groups are presented in
Table 1. Only ten (0.54%) patients’ creatinine lev-
els were higher than 1.3 mg/dL.
The number of CAD patients increased as the
quartile of cystatin C increased, with a remarkable
statistical difference between cystatin C groups
(c2: 59.7 and p < 0.001). Independent predictors of
incident CAD determined by logistic regression
were: cystatin C, hs-CRP, eGFR, HDL cholesterol
and systolic blood pressure, after adjustments for
age, creatinine, eGFR, gender, presence hyperten-
sion and diabetes mellitus, LDL cholesterol, dias-
tolic blood pressure and homocysteine (Table 2).
Every 0.1 mg/L increase in cystatin C, 1 mg/L in-
crease in hs-CRP, 0.1 mmol/L decrease in HDL and
10% decrease in eGFR caused a 32%, 12%, 6.1% and
23% increase in the risk of having CAD, respectively.
In ROC curve analyses, among the parameters
investigated for the prediction of CAD, cystatin C
had the most discriminatory power for the occur-
Table 1. Variables of study population according to cystatin C quartiles.
Variable Serum cystatin C levels [mg/L] p
< 0.65 0.65–0.82 0.83–0.99 ≥ 1.0
(ANOVA)
(n = 47)  (n = 46)  (n = 46)  (n = 47)
Age (years) 54.2±5.0* 54.3±8.9D 56.7± 8.8 59.1±8.1  0.005
Male/female 39/8 29/17 34/12 31/16 0.170a
Hypertension (%) 20 (42.6) 17 (36.9) 24 (52.2) 32 (68.1) 0.025a
Systolic blood pressure [mm Hg] 130.6±15.9† 125.5±11.1 122.2±14.3 124.7±11.9  0.023
Diastolic blood pressure [mm Hg] 83.2±10.0 79.8±8.5 78.5±9.6 80.0±9.2  0.081
Diabetes (%) 22 (46.8) 13 (28.3) 17 (36.9) 16 (34.1) 0.344a
Smoking (%) 14 (29.8) 16 (34.8) 15 (32.6) 19 (40.4) 0.337a
Heart rate [bpm] 71.8±8.8 73.1±8.5 75.1±13.1 75.3±10.1 0.308
Creatinine [mg/dL] 0.77±0.19†, * 0.84±0.14D 0.93±0.15¶ 1.15±0.39 < 0.001
eGFR (%) 115±33†, ‡, * 106±24 100±22 78±28 < 0.001
Total cholesterol [mmol/L] 200±52‡ 169±32 186±45 187±46 0.010
HDL cholesterol [mmol/L] 52±10†, ‡, * 43±10 42±9.7 40±11 < 0.001
LDL cholesterol [mmol/L] 115±47 101±29 116±37 109±35 0.211
Triglycerides [mmol/L] 170±106 132±54D 168±82 181±80 0.026
Homocysteine [mg/dL] 1.8±0.7†, ‡, * 2.0±0.8 2.2±0.5 3.2±1.2 < 0.001
hs-CRP [mg/L] 5.3±4.0* 5.6±5.4 6.3±7.1 8.7±7.7 0.037
CAD severity score 1.5±5.3†, ‡, * 10.0±18.5D 18.7±19.2 25.2±21.3 < 0.001
Normal coronary arteries (score 0) (%) 42 (89.3) 27 (58.7) 13 (28.3) 10 (21.3)
Mild CAD (score 1–20) (%) 3 (6.3) 9 (19.7) 15 (32.6) 10 (21.3) < 0.001a
Severe CAD (score > 20) (%) 2 (4.4) 10 (21.7) 18 (39.1) 27 (57.4)
LV end-diastolic volume [mL] 115±38* 118±23 125±47 146±76 0.022
LV end-systolic volume [mL] 46±18* 41±19D 52±36 66±56 0.012
LV ejection fraction (%) 62.5±6.8* 65.1±6.8D 61.9±7.8 55.9±9.7 < 0.001
LV mass index [g/m2] 112±32* 120±35 117±40 146±58 0.001
LV hypertrophy (%) 11 (23.4) 16 (34.8) 16 (34.8) 22 (46.8) 0.024a
Data is expressed as mean ± SD or number; eGFR — estimated glomerular filtration rate; hs-CRP — high sensitive C reactive protein; CAD — coro-
nary artery disease; LV — left ventricle; ‡p < 0.05 between patients in cystatin C < 0.65 and 0.65–0.82; †p < 0.05 between patients in cystatin C < 0.65
and 0.83–0.99; *p < 0.05 between patients in cystatin C < 0.65 and ≥ 1.0; §p < 0.05 between patients in cystatin C 0.65–0.82 and 0.83–0.99;
Dp < 0.05 between patients in cystatin C 0.65–0.82 and ≥ 1.0; ¶p < 0.05 between patients in cystatin C 0.83–0.99 and ≥ 1.0; a p value from c2 test
377
Mevlut Koc et al., Clinical utility of cystatin C
www.cardiologyjournal.org
rence of CAD across the entire population. The
AUCs in predicting CAD were 0.811, 0.746, 0.742,
0.637, 0.713 and 0.652 for cystatin C, creatinine,
eGFR, hs-CRP, HDL cholesterol and systolic blood
pressure, respectively (Table 3). The ROC curves
for cystatin C, creatinine, eGFR, hs-CRP are shown
in Figure 1. As well as between cystatin C and cre-
atinine, significant AUC differences were found
between other variables (p < 0.05). The ROC curve
analysis for cystatin C and hs-CRP had the highest
and smallest AUC value respectively. Therefore,
the most significant AUC difference was found between
cystatin C and hs-CRP (p < 0.01). A 0.82 mg/L cut-off
value of cystatin C predicted CAD with a sensitivi-
ty and specificity of 75.5% and 75.0%, respective-
ly. Cut-off value, sensitivity and specificity of oth-
er variables are shown in Table 3.
The association between cystatin C and CAD
severity score is depicted in Figure 2. Linear re-
gression analysis showed that cystatin C, hs-CRP
and HDL cholesterol levels were the most significant
predictors of CAD severity (b = 0.258, p < 0.001;
b = 0.249, p < 0.001 and b = –0.227, p = 0.001,
respectively; the explained variance for the CAD
severity score [R2] was 0.309).
Cystatin C was significantly correlated with
serum creatinine, homocysteine, hs-CRP, HDL
cholesterol and eGFR (p < 0.01 for each). The most
significant predictors of serum homocysteine level
were cystatin C level and CAD severity score (b =
= 0.450, p < 0.001 and b = 0.176, p = 0.031, ad-
justed for hs-CRP, eGFR, age and blood pressure;
and the explained variance of homocysteine (R2) was
0.268]. Although hs-CRP significantly correlated
with cystatin C, only CAD severity score and creat-
inine concentration predicted hs-CRP (b = 0.297,
p < 0.001 and b = 0.210, p = 0.003 respectively).
Since impaired renal function constitutes a sub-
stantial risk for CAD, we analyzed various tests that
reflect renal function to predict CAD. Among these
tests, cystatin C was found to be superior to creat-
inine or eGFR for its sensitivity and specificity in
predicting CAD (Fig. 1).
Discussion
Our study has shown a strong correlation be-
tween cystatin C and the presence or severity of
CAD, low HDL, creatinine and homocysteine levels
in patients with suspected CAD. However, the cor-
relation was weak between cystatin C and hs-CRP.
Several lines of study have demonstrated an
association between renal impairment and athero-
sclerotic vascular disease [1–3, 22]. Wang et al. [15]
reported that mild renal impairment, determined by
elevated cystatin C, was associated with the occur-
Table 2. Multivariate logistic regression analysis for predicting the presence of coronary atherosclerosis.
Variable Odds ratio 95% CI P
Cystatin C (for each 0.1 mg/L) 1.316 1.086–1.594 0.005
hs-CRP [mg/L] 1.124 1.013–1.248 0.027
eGFR (%) 0.977 0.958–0.996 0.017
HDL cholesterol [mmol/L] 0.950 0.911–0.989 0.014
Systolic blood pressure [mm Hg] 0.940 0.906–0.975 0.001
CI — confidence interval; eGFR — estimated glomerular filtration rate; hs-CRP — high sensitive C reactive protein
Table 3. Receiver-operating characteristic analyses for cystatin C, creatinine, eGFR, hs-CRP,
HDL cholesterol levels and systolic blood pressure in predicting coronary atherosclerosis.
Variable Area under curve (95% CI) P Cut-off Sensitivity Specificity
Cystatin C 0.811 (0.748–0.873) < 0.001 0.82 mg/L 75.5% 75.0%
Creatinine 0.746 (0.676–0.815) 0.001 0.90 mg/dL 74.7% 71.2%
eGFR 0.742 (0.671–0.813) < 0.001 95% 72.8% 69.1%
hs-CRP 0.637 (0.556–0.717) 0.001 4 mg/L 62.8% 62.0%
HDL cholesterol 0.713 (0.639–0.787) < 0.001 42 mmol/L 71.7% 62.7%
Systolic blood pressure 0.652 (0.574–0.729) < 0.001 125 mm Hg 60.9% 54.3%
CI — confidence interval; eGFR — estimated glomerular filtration rate; hs-CRP — high sensitive C reactive protein
378
Cardiology Journal 2010, Vol. 17, No. 4
www.cardiologyjournal.org
rence and severity of CAD; however creatinine and
eGFR were not able to predict CAD occurrence in
their study. Likewise, Koenig et al. [10] reported
that cystatin C was superior to creatinine or eGFR
for predicting cardiovascular events. A prospective
cohort study by Luc et al. [14], showed an associa-
tion between cystatin C and the incidence of CAD.
However, when CRP was included in the analyses,
cystatin C lost its significance. This suggests the
predictive value of cystatin C is not independent.
In another study, cystatin C independently predict-
ed smooth CAD lesions, but not complex lesions or
CAD severity [16]. Our study is in accordance with
the findings of Wang et al. [15] and Koenig et al.
[10] that, among markers of renal function, cysta-
tin C and eGFR are significantly and independent-
ly related to the presence of CAD, but only cysta-
tin C predicts CAD severity. Additionally, results
of our study are consistent with the observation that
creatinine is not sensitive to detect mild impair-
ments in renal function, since we observed no as-
sociation between serum creatinine and the pres-
ence or severity of CAD. Moreover, we found that
cystatin C is more sensitive and specific than CRP
in identifying CAD.
A cut-off value of cystatin C to anticipate the
presence of CAD has not been suggested to date.
We analyzed the optimal cut-off value of cystatin C
in our study, which revealed optimal cut-off as
0.82 mg/L with a 75.5% and 75% sensitivity and
specificity respectively.
A number of previous studies reported a posi-
tive correlation between cystatin C and certain
inflammatory markers such as fibrinogen, hs-CRP,
IL-6 and TNF-a [9, 10, 14] and they hypothesized
that alterations of serum cystatine C levels could
be due to the inflammatory response which is evi-
dent in atherosclerosis. However, few studies have
not found an association between CRP and
cystatin C in both stable and unstable CAD [12, 16].
Singh et al. [23] investigated the association between
renal function markers and inflammatory parame-
ters; this revealed an independent association be-
tween eGFR and CRP or fibrinogen. Although there
was an association between cystatin C and CRP or
fibrinogen in this study, this association was lost fol-
lowing the inclusion of eGFR into the analyses.
Our results confirm previous studies [12, 23]
that demonstrate the positive correlation between
cystatin C and CRP. However, in our study, the
most significant predictors of CRP were found to
be CAD severity and serum creatinine.
Elevated homocysteine level is a well-known
cardiac risk factor for the development of athero-
Figure 1. Receiver-operating characteristic (ROC) curve
analyses and the area under ROC curves (AUROC) for
cystatin C, creatinine, estimated glomerular filtration
rate (eGFR) and high sensitive C reactive protein (hs-
-CRP) in predicting the presence of coronary artery dise-
ase (CAD).
Figure 2. The relation between cystatin C and coronary
artery disease (CAD) severity score.
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sclerosis [24]. In contrast to serum creatinine, se-
rum cystatin C has independently predicted fasting
total homocysteine level in both stable CAD and
renal transplantation patients with normal serum
creatinine [25, 26]. Likewise, the most significant
parameters in our study in predicting serum ho-
mocysteine were serum cystatin C level and CAD
severity score.
Limitations of the study
There were a number of limitations to our
study. Firstly, the sample size of our study was rel-
atively small and we did not consider medication in
our analyses. Secondly, renal function is closely
related to the outcome of stable [10, 22] and unsta-
ble CAD [12, 13] patients and we did not evaluate
cardiovascular events that warrant prospectively
designated studies. Finally, we did not collect
24-hour urine for true GFR, which is the ‘gold stan-
dard’ method of assessing renal function.
Conclusions
The results of our study indicate that serum
cystatin C is as relevant as CRP (which is current-
ly widely used in predicting CAD). Moreover, cys-
tatin C is superior to other markers of renal func-
tion in anticipating CAD risk. There is a consider-
able association between serum cystatin C and
biochemical cardiovascular risk factors such as ho-
mocysteine, low HDL and CRP. With these results,
we suggest that cystatin C could be used as a mark-
er in daily practice to predict the presence or se-
verity of atherosclerosis in suspected stable CAD
patients.
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